South Korea Companion Animal Cardiac Drugs Market Size & Outlook
The companion animal cardiac drugs market in South Korea is expected to reach a projected revenue of US$ 56.8 million by 2033. A compound annual growth rate of 11.1% is expected of South Korea companion animal cardiac drugs market from 2026 to 2033.
- Animal Health
- Animal Pharmaceuticals & Biotechnology
- Companion Animal Cardiac Drugs Market Outlook
- Animal Pharmaceuticals & Biotechnology
Revenue, 2025 (US$M)
$25.2
Estimate, 2026 (US$M)
$27.2
Forecast, 2033 (US$M)
$56.8
CAGR, 2026 - 2033
11.1%
Global Market
Related Markets
Prism AI by Grand View ResearchFree to try
Ask a question about the companion animal cardiac drugs market
Every figure cited from GVR research
South Korea companion animal cardiac drugs market highlights
- The South Korea companion animal cardiac drugs market generated a revenue of USD 25.2 million in 2025 and is expected to reach USD 56.8 million by 2033.
- The South Korea market is expected to grow at a CAGR of 11.1% from 2026 to 2033.
- In terms of segment, dogs was the largest revenue generating animal type in 2025.
- Cats is the most lucrative animal type segment registering the fastest growth during the forecast period.
Companion animal cardiac drugs market data book summary
| Market revenue in 2025 | USD 25.2 million |
| Market revenue in 2033 | USD 56.8 million |
| Growth rate | 11.1% (CAGR from 2026 to 2033) |
| Largest segment | Dogs |
| Fastest growing segment | Cats |
| Historical data | 2021 - 2024 |
| Base year | 2025 |
| Forecast period | 2026 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Dogs, Cats, Horses, Others Animal Type |
| Key market players worldwide | Boehringer Ingelheim, CEVA Inc, Elanco Animal Health Inc, Virbac SA, Zoetis Inc Class A, Dechra Pharmaceuticals, Bimeda, Biogenesis Bago, Merck KGaA, Vetoquinol SA |
Other key industry trends
- In terms of revenue, South Korea accounted for 1.3% of the global companion animal cardiac drugs market in 2025.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
- In Asia Pacific, Japan companion animal cardiac drugs market is projected to lead the regional market in terms of revenue in 2033.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 149.5 million by 2033.
No credit card required*
Publish Date: Jul 22, 2026
Customize the Report
20% free customization
- Include
- Countries, segments, points
- Tailor
- To your product definition
- Extend
- Deeper competitor detail
- Or
- A fully bespoke study
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Companion Animal Cardiac Drugs Market Scope
Companion Animal Cardiac Drugs Market segmentation & scope
Companion Animal Cardiac Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Zoetis Inc Class A | View profile | 14,100 | 10 Sylvan Way, Parsippany, NJ, United States, 07054 | www.zoetis.com |
| Virbac SA | View profile | 5,400 | 2065m LID, 1 ere avenue, Carros, France, 06516 | www.virbac.com |
| CEVA Inc | View profile | 424 | 15245 Shady Grove Road, Suite 400, Rockville, MD, United States, 20850 | www.ceva-dsp.com |
| Elanco Animal Health Inc | View profile | 9,800 | 2500 Innovation Way, Greenfield, IN, United States, 46140 | www.elanco.com |
| Boehringer Ingelheim | View profile | 10001+ | Ingelheim Am Rhein, Rheinland-Pfalz, Germany, Europe | www.boehringer-ingelheim.com/ |
| Vetoquinol SA | View profile | 2,483 | Magny-Vernois, BP 189, Lure cedex, France, 70204 | www.vetoquinol.com |
| Dechra Pharmaceuticals | View profile | 501-1000 | Northwich, Cheshire, United Kingdom, Europe | www.dechra.com |
| Biogenesis Bago | View profile | 501-1000 | Garín, Buenos Aires, Argentina, South America | www.biogenesisbago.com/en/ |
| Bimeda | View profile | 1001-5000 | Dublin, Dublin, Ireland, Europe | www.bimeda.com/ |
South Korea Companion Animal Cardiac Drugs Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Companion Animal Cardiac Drugs Market Outlook will help companies and investors design strategic landscapes.
Dogs was the largest segment with a revenue share of 68.65% in 2025.
Horizon Databook has segmented the South Korea companion animal cardiac drugs market based on dogs, cats, horses, others animal type covering the revenue growth of each sub-segment from 2021 to 2033.
- South Korea Companion Animal Cardiac Drugs Market Animal Type Outlook (Revenue, USD Million , 2021-2033)
- Dogs
- Cats
- Horses
- Others Animal Type
- South Korea Companion Animal Cardiac Drugs Market Product Outlook (Revenue, USD Million , 2021-2033)
- Pimobendan
- Spironolactone and Benazepril Hydrochloride
- Furosemide
- Others Product
- South Korea Companion Animal Cardiac Drugs Market Indication Outlook (Revenue, USD Million , 2021-2033)
- Congestive Heart Failure
- Myocardial (Heart Muscle) Disease
- Arrhythmias
- Others Indication
- South Korea Companion Animal Cardiac Drugs Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Veterinary Hospitals & Clinics
- Others End Use
- South Korea Companion Animal Cardiac Drugs Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
- Hospital/ Clinic Pharmacy
- Retail
- E-Commerce
Reasons to subscribe to Companion Animal Cardiac Drugs Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Companion Animal Cardiac Drugs Market Outlook databook
- Our clientele includes a mix of Companion Animal Cardiac Drugs Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea Companion Animal Cardiac Drugs Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into South Korea Companion Animal Cardiac Drugs Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
South Korea Companion Animal Cardiac Drugs Market, 2021-2033 (US$M)
South Korea companion animal cardiac drugs market statistics, by animal type, 2021-2033 (US$M)
